Every headline mentioning Merck from CNBC, Yahoo Finance and Investing.com over the last 30 days, each scored for sentiment and importance. Updated automatically through the trading day.
Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to insurance giants. Here is who got…
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Investors were still buying it in the afterglow of its latest quarterly earnings release.
Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.
Merck & Co., Inc. announced its third-quarter 2026 financial results, reporting total worldwide sales of $18.1 Billion, which represents 5% growth. For the third quarter of 2026, Generally Accepted Accounting Principles (GAAP) earnings…
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
Moderna released full data on its closely watched cancer vaccine developed with Merck.
Moderna released full data on its closely watched cancer vaccine developed with Merck.
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.
His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.